The onset of the deadly global Coronavirus is emboldening the Trump administration to re-examine the United States pharmaceutical industry, which manufactures the majority of its antibiotics, medicines and other medical products in China, Dr. Ramin Oskoui told The Sara Carter Show, on Thursday.

Dr. Oskoui, CEO of Foxhall Cardiology, said because 95 percent of all antibiotics are manufactured in China and this poses a very real national security threat to the United States, particularly when dealing with the global pandemic COVID-19.

He said that the pandemic has spurred important discussions on the failure of the United States pharmaceutical companies to manufacture the much needed and critical medicines, including medical equipment inside the country. Dr. Oskoui warned that outsourcing the manufacturing of much needed medicine leaves Americans extremely vulnerable and dependent on China.

“I think we need to have an open strong conversation not behind the scenes, not behind closed doors, but openly about drug companies re-shoring, making medications in the United States,” said Dr. Oskoui. “It’s unacceptable that the Chinese have us by the throat and make 95 percent of our antibiotics. And that’s the critical thing that’s got to change soon…actually make it a priority.”

According to a recent article in the The New York Times, the Trump administration is preparing an executive order, “which could be released in the coming days, that would close loopholes allowing the government to purchase pharmaceuticals, face masks, ventilators and other medical products from foreign countries.”

The paper noted that the increase the demand for American-made drugs and medical products should provide the American pharmaceutical companies the incentive to not outsource their manufacturing to countries, like China.

One example of possible backlash from China, said Dr. Oskui is recent newspaper reports emanating from China suggest the Chinese government “may just flip the switch and stop stop our access to those things.”

“The United States of America should never be in that position,” he said. “I think we need to turn to people we know that worked for Pfizer, worked for Merck, work for Amgen, work for Gilead, worked for Bristol-Myers Squibb the U.S. drug companies and say ‘you know we understand that you have few share obligations to your shareholders but you also have an obligation to your fellow Americans, as American citizens as an American drug companies’ you need to start making it here just because you can make huge profits abroad we shouldn’t be vulnerable to economic and political blackmail and vulnerable to the medical downside of these drugs being manufactured off our shores.”

“There’s no reason we can’t be drug self-sufficient,” he added. “We have the brain trust, we have the┬áland to build these factories. We shouldn’t be offshoring stuff like this and that that’s really got to end and that needs to be a discussion that we have.”